B cells are generally considered to be positive regulators of the immune response because of their capability to produce antibodies, including autoantibodies. The production of antibodies facilitates optimal CD4 1 T-cell activation because B cells serve as antigen-presenting cells and exert other modulatory functions in immune responses. However, certain B cells can also negatively regulate the immune response by producing regulatory cytokines and directly interacting with pathogenic T cells via cell-to-cell contact. These types of B cells are defined as regulatory B (Breg) cells. The regulatory function of Breg cells has been demonstrated in mouse models of inflammation, cancer, transplantation, and particularly in autoimmunity. In this review, we focus on the recent advances that lead to the understanding of the development and function of Breg cells and the implications of B cells in human autoimmune diseases.
INTRODUCTION B-cell development in the bone marrow is a dynamic and complex process involving a delicate balance between cell proliferation and apoptotic selection. This balance results in the generation of functional B cells that are responsible for eliciting humoral immunity. [1] [2] [3] The concept that suppressor B cells could regulate the immune response originated in 1974, when the ability of B cells to suppress delayed-type hypersensitivity responses in guinea pigs was described. 4, 5 However, the term 'regulatory B cells', which defines B-cell subsets with regulatory properties, was first introduced by Mizoguchi and Bhan nearly 30 years later. 6 Similar to regulatory T (Treg) cells, the regulatory function of B cells is exerted via the production of regulatory cytokines, such as IL-10 and TGF-b, and the ability to express inhibitory molecules that suppress pathogenic T cells and autoreactive B cells in a cell-tocell contact-dependent manner. 7 Until recently, the exact origin and molecular identity of regulatory B (Breg) cells remained elusive. Accumulating evidence suggests that the Breg cell population is heterogeneous, meaning that this population can be derived from all B cells under the correct stimulatory context and time. 8 It has been postulated that Breg cells can exert their suppressive functions with different mechanisms in various mouse models of disease, including inflammation, cancer and autoimmunity. 9 Moreover, dynamic changes in Breg cells have been associated with the progression of human autoimmune diseases. 10, 11 Here, we review the recent literature studying both the phenotypic and functional characterization of Breg cells and the implications B cells have on the pathogenesis of autoimmune diseases.
IDENTIFICATION OF BREG CELLS
Despite the observations made in the 1970s that B cells with suppressive functions possibly existed, the potential role of B cells with regulatory functions in inflammatory and autoimmune diseases has only been recently appreciated. Janeway and colleagues first observed that B10.PL mice lacking B cells suffered an unusually severe and chronic form of experimental autoimmune encephalomyelitis (EAE), indicating that B cells have regulatory properties in a mouse model of EAE. 12 Subsequently, it was found that B cells affected this autoimmune disease by regulating IL-10. 13 Mizoguchi and Bhan were the first to introduce the term 'regulatory B cells' to describe these B-cell subsets with regulatory properties. 6 While studying the putative pathogenic role of B cells in the development of colitis, the authors unexpectedly observed that T cell receptor alpha (TCRa) 2/2 mice that were crossed with B cell-deficient mice spontaneously developed an earlier onset of colitis that was more severe compared to TCRa 2/2 mice.
expression of CD1d and suppressed the progression of intestinal inflammation by downregulating inflammatory cascades associated with IL-1 and signal transducer and activator of transcription 3 (STAT3) activation. 15 Early studies have revealed that B-1 cells in the peritoneal cavity are a major source of B cell-derived IL-10. 16 Upon IL-12 stimulation, B1a cells, but not B-1b cells, have the ability to produce IL-10. 17 Recently, the production of Th2 cytokines by conventional B2 cells has been extensively investigated. The marginal-zone (MZ) B cells have been shown to regulate immunity by producing IL-10 in response to CpG stimulation in a mouse model of lupus. 18 Moreover, splenic transitional 2-MZ precursor (T2-MZP) B cells that express high amounts of CD21, CD23, CD24, IgM and CD1d from both naive and arthritic mice are capable of producing IL-10. Remarkably, the regulatory function of T2-MZP cells depends on IL-10 production because T2-MZP cells from IL-10 2/2 DBA mice show no protection against the development of arthritis. 19 Tedder and colleagues have identified a subset of IL-10-producing B10 cells that contain the unique phenotype CD1d hi CD5
1 . These cells share certain phenotypic markers with B-1a, MZ B and T2-MZP cells.
20 B10 cells normally represent 1%-2% of splenocytes in wild-type mice and approximately 10% in hCD19 transgenic mice. Notably, IL-10 production has been found to be restricted to this B10 cell subset. Interestingly, IL-10 production was decreased in CD19 Although great progress has been made in the characterization of Breg cells, the cell surface markers and/or specific transcription factor(s) that are unique to Breg cells have not been defined in mice and humans. Most of the currently identified Breg cells exert their suppressive function at least partially through the production of regulatory cytokines, such as IL-10 and TGF-b. This production of regulatory cytokines has been demonstrated by both in vitro functional assays and in vivo mouse studies.
BREG CELLS IN AUTOIMMUNE DISEASES
The regulatory functions of Breg cells have been extensively characterized in various animal models of inflammation, cancer and autoimmune diseases. B cells are generally considered to play a pathogenic role in the development of autoimmune diseases because B cells produce autoantibodies that cause target tissue damage. 26 However, autoantibodies can also exert a protective effect via the clearance of apoptotic cells and reduction of autoantigen load. 27 Moreover, B cells also act as antigen-presenting cells, which are cells that contribute to the activation and amplification of naive, activated and autoreactive T-cell responses. [28] [29] [30] It has been reported that antigens presented by resting B cells can induce the differentiation of tolerogenic CD4
1 T cells. 31, 32 Furthermore, B cells, similar to T cells, can be defined as B effector 1 and 2 cells. B effector 1 cells produce Th1-associated pro-inflammatory cytokines, including tumor-necrosis factor (TNF)-a, IFN-c and IL-12, whereas B effector 2 cells produce Th2-associated cytokines, including IL-4 and IL-13. 33 Notably, certain regulatory B cells that produce IL-10 or TGF-b have recently been shown to possess inhibitory functions in autoimmune diseases. 6 Thus, current studies on the functional implications of Breg cells in the pathogenesis of autoimmune diseases can facilitate the development of combined therapies for autoimmune diseases. In the following sections, the role of Breg cells in mouse models of various autoimmune diseases, including rheumatoid arthritis, autoimmune diabetes, autoimmune encephalomyelitis and lupus, will be discussed.
Breg cells in experimental arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that is characterized by inflammation in the synovium. This inflammation is associated with the infiltration of activated T cells, B cells and macrophages, as well as the progressive destruction of cartilage and bone structures, which eventually leads to joint destruction and deformity. 34 RA is a common systemic autoimmune disease that has a prevalence of approximately 0.5%-1% in the adult population. 35 An animal model of human RA exists whereby collagen-induced arthritis (CIA) is induced in a susceptible strain of DBA/1J mice that are immunized with heterologous type II collagen emulsified in complete Freund's adjuvant. 36 CIA is characterized by severe swelling of the paws, extensive synovial hyperplasia, cartilage damage, bone erosion and joint ankylosis. [36] [37] [38] [39] Collagen immunization induces chronic inflammatory arthritis, which is the result of infiltration of CD4 1 T cells into the synovial membrane and the production of collagen-specific IgG autoantibodies by B cells. 40 Many types of immune cells, including natural killer cells, have been shown to possess a regulatory function in the development of autoimmune arthritis. 41 In CIA mice, B-cell depletion using the CD20 monoclonal antibody (mAb) significantly ameliorates disease severity. 42 Interestingly, B-cell depletion before collagen immunization delays disease onset and autoantibody production and markedly diminishes the severity of arthritis as indicated by both clinical symptoms and histological changes in joint tissue. However, B-cell depletion after collagen immunization does not show any significant effect on arthritis progression or disease severity. These observations suggest that B cells may play a more prominent regulatory role during the initiation of disease. In CIA mice, IL-10-producing B-cell subsets with varying phenotypes and origins have also been identified during arthritis development. Mauri et al. have performed a comprehensive study that examines whether adoptive transfer of activated B cells from arthritic mice has an inhibitory effect on CIA. 43 Mauri and colleagues found that the in vitro activation of splenic arthritogenic B cells with collagen and a CD40 mAb resulted in IL-10 production. B cells that were injected intraperitoneally into recipient DBA/1-T-cell Ag receptor b-transgenic mice that were concurrently immunized with collagen significantly reduced the incidence and severity of arthritis and markedly inhibited Th1 cell differentiation. Moreover, in vitro- 19 Administration of apoptotic thymocytes to mice up to 1 month before the clinical onset of CIA has also been shown to have protective effects on joint inflammation and bone destruction. 44 Activated splenic B cells respond directly to apoptotic cell treatment by increasing the secretion of IL-10, which is important for inducing T cell-derived IL-10. Moreover, the passive transfer of B cells from apoptotic cell-treated mice provides significant protection against developing arthritis. These findings suggest that certain subsets of IL-10-producing B cells generated in vivo can suppress autoimmune pathogenesis. This notion is supported by our recent findings that in vitro induced B10 cells can suppress the development of arthritis and decrease joint pathology in CIA mice. 45, 46 Adoptive transfer of in vitro expanded B10 cells in mice on the day of the second collagen immunization resulted in a marked delay in the onset of arthritis and a reduced severity of both clinical symptoms and joint damage. This delay of onset was accompanied by a substantial reduction in the number of pathogenic IL-17-producing CD4
1 T cells. Thus, Breg cells expanded in vitro can be a potential treatment for autoimmune arthritis.
Breg cells in autoimmune diabetes
Type 1 diabetes (T1D) is characterized by the destruction of insulin-producing pancreatic b cells. This destruction is primarily mediated by CD4
1 and CD8 1 T cells. 47 In non-obese diabetic (NOD) mice, which is a spontaneous model of human T1D, the onset of diabetes is initiated at the age of 13-15 weeks, and approximately 80% of female mice and 20% of male mice develop diabetes by the age of 30 weeks. 48 There is increasing evidence that B cells play a pathogenic role in the initiation of T1D. B cells are among the earliest cells to infiltrate the pancreatic islets in NOD mice, which is where they organize with T cells into lymphoid structures within germinal centers that promotes the selection of autoreactive B cells. 49, 50 These ectopic lymphoid structures, which consist of a central zone of T cells surrounded by B cells, begin to generate at the early stage of peri-insulitis. 51 Because B cell-deficient NOD mice fail to develop diabetes, targeting B cells may be a potential approach to treating b-cell mediated autoimmune diabetes.
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In 5-week-old female NOD mice treated with CD20 mAbs for a short amount of time, approximately 95% of B cells were depleted, which subsequently led to reduced insulitis. Moreover, diabetes was prevented in more than 60% of the littermates. However, treating 15-week-old NOD female mice with a CD20 mAb substantially delays the onset of diabetes, but does not prevent the disease. 53 Recent studies conducted by Grey and colleagues have shown that B-cell depletion delays and reduces diabetes by increasing the number of CD25 1 Foxp3 1 CD4 1 Treg T cells, thereby enforcing long-term tolerance. 54 Moreover, studies by Smith and Tedder have suggested that Breg cells, such as B10 cells, may represent a significant component of the reconstituted B-cell pool after B-cell depletion. 55 These findings suggest an involvement of Breg cells in the development of diabetes.
There is compelling evidence that activated B cells can maintain immune tolerance because the transfer of activated B cells protects NOD mice from diabetes. 56, 57 Repeated intravenous transfer of BCR-activated B cells into 5-to 6-week-old NOD mice delays the onset and reduces the incidence of diabetes, while treatment starting at 9 weeks of age only delays diabetes onset. The therapeutic effect from transfusing activated B cells from NOD mice correlates with the polarization of CD4
1 T cells toward a Th2 phenotype in recepient NOD mice. 
Breg cells in EAE Multiple sclerosis (MS) is a prototypic T cell-mediated autoimmune disease that results in the demyelination of cells in the central nervous system (CNS). This demyelination is mediated by CD4
1 T cells specific for myelin oligodendrocyte glycoprotein and other autoantigens in the central nervous system. 59 EAE is a mouse model of human MS. Accumulating evidence has suggested that B cells also play a pathogenic role in EAE. 12, 60, 61 However, it has been reported that B cell-deficient mice develop a more severe and non-remitting form of EAE. 12, 60 Moreover, CD20 1 B cell depletion after EAE development dramatically suppresses the disease symptoms.
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Although B-cell depletion ameliorates ongoing EAE, B-cell depletion occurring before EAE induction exacerbates the disease, suggesting that the Breg cells that negatively regulate inflammatory reactions are possibly depleted. 63 Furthermore, the regulatory functions of B cells during EAE have been linked to the production of IL-10 because adoptive transfer of wildtype B cells, rather than IL-10 2/2 B cells from mMT mice, decreases the severity of EAE. B cells from recovered mice produce IL-10, which is important for attenuating pro-inflammatory Th1 responses. Importantly, in the absence of IL-10-producing B cells, mice are not able to recover from EAE. 60, 64 In a recent study, fusokine GIFT15-induced Breg cells are shown to secrete IL-10 and express MHC I, MHC II, and surface IgM and IgD. Moreover, mice with EAE undergo complete remission after the intravenous transfer of GIFT15-Breg cells. These cells function by suppressing neuro-inflammation. 21 Therefore, IL-10-producing B cells have been identified as important regulators in controlling EAE. Recently, Tedder and colleagues characterized the overlapping and differential roles of Breg and Treg cells in shaping the course of EAE immunopathogenesis. 65 Adoptively transferred B10 cells can directly influence EAE pathogenesis by producing IL-10. Interestingly, the number of B10 cells expands quickly in the spleen but not in the CNS, which is consistent with the regulatory function of B10 cells involved in disease initiation. Furthermore, transfer of antigen-sensitized B10 cells into wild-type mice dramatically reduces EAE initiation, but B10 cells could not inhibit ongoing EAE progression. However, the number of Treg cells expanded markedly within the CNS during disease progression. This expansion negatively regulated the late phase of EAE. Thus, these findings suggest that Breg cells play a predominant role in the control of disease initiation, whereas Treg cells exert their regulatory function during the late-phase of disease.
Breg cells in murine lupus
Systemic lupus erythematous (SLE) is a systemic autoimmune disease that is characterized by high autoantibody production, increased immune complex deposition, and multiple organ damage. Both T and B cells contribute to the pathogenesis of human SLE. 66, 67 NZB/NZW (NZB/W) F1 hybrid mice develop a spontaneous lupus-like disease, which is characterized by immune complex-mediated glomerulonephritis that is associated with IgG autoantibody production against nuclear Ags, including dsDNA, RNA, chromatin and histones. 68 The prominent characteristics of NZB/W F1 mice include the expansion of B-1a and MZ B cells, activation of polyclonal B cells, and high serum levels of IgM and IgG. [69] [70] [71] [72] MRL/lpr mice also spontaneously develop a similar lupus-like disease. 73 Therefore, both NZB/W F1 and MRL/lpr mouse models have been extensively used for studying human SLE. When 12-to 28-week-old NZB/W F1 mice receive treatment with a low dose of the CD20 mAb, spontaneous disease progression is significantly delayed. In contrast, B-cell depletion initiated in 4-weekold mice promotes disease onset, most likely due to the depletion of IL-10-producing Breg cells. 74 It has been shown that there is significant expansion of B10 cells in young NZB/W F1 mice. 65 Therefore, different B-cell populations can play either protective or pathogenic roles during disease pathogenesis because the timing of B-cell depletion has significant effects on disease progression in NZB/W F1 mice. To examine the roles of B cells in disease pathogenesis in NZB/W F1 mice, CD19 2/2 NZB/W mice were generated. The production of anti-nuclear Abs was remarkably delayed in CD19 10 This phenotype has been previously associated with immature transitional B cells. 77, 78 However, these B cells were able to produce IL-10 in response to CD40 stimulation. However, CD19
1 CD24 hi CD38 hi B cells isolated from the peripheral blood of patients with SLE lacked the suppressive capacity possessed by their counterparts in healthy individuals. Moreover, comparisons between B cells from SLE patients and healthy controls indicate that the defect in IL-10-production in response to CD40 stimulation in B cells from SLE patients is possibly due to altered activation of STAT3. 10 Interestingly, SLE patients who received rituximab treatment had an increased ratio of CD19 82 Although current findings cannot reconcile the different phenotypes of human Breg cells, it is clear that Breg cells exist in human blood and lymphoid organs. These cells have regulatory functions that are partially dependent on IL-10 production.
Similar to findings in animal models, the relative contribution of different immune components to the pathogenesis of human autoimmune disease differs from one disease to another. B cells may play either a crucial role in the initiation of the disease or contribute to autoimmune pathogenesis after disease onset. 40 Recently, B-cell depletion strategies have been used to treat patients with autoimmune diseases. In RA patients, B-cell depletion using rituximab significantly diminished ongoing joint inflammation, but the recrudescence of disease activity was often accompanied by B-cell recovery. [83] [84] [85] In human MS, B-cell depletion appears to be more effective after the onset of disease. B-cell depletion after the onset of the symptoms can ameliorate disease progression. 86 Clinical studies have shown that B-cell depletion with rituximab improves the clinical manifestations of SLE. 87 These clinical studies have suggested that B-cell depletion is an effective therapy for treating autoimmune diseases. However, B-cell depletion may exacerbate disease in some autoimmune conditions. For example, B-cell depletion has been shown to exacerbate ulcerative colitis and trigger psoriasis, which are both Th1-mediated autoimmune conditions. 88, 89 These intriguing findings may indicate the existence of Breg cells that modulate T cell-mediated inflammatory responses in vivo.
Taken together, B cells, autoantibodies and T cells are all involved in the development of autoimmune diseases and have unique functions in each autoimmune disease. B cells not only produce autoantibodies and act as antigen-presenting cells for CD4 1 T-cell activation, but also serve as negative regulators that dampen harmful immune responses. Therefore, the time window for depleting B cells or transferring Breg cells is important because the changes in immunological balance may result in either exacerbation or amelioration of disease progression.
MICRO-ENVIRONMENTAL SIGNALING IN MODULATING BREG CELL GENERATION
No common surface markers or specific transcription factor(s) have been identified yet that define both human and mouse Breg cells. Moreover, Breg cells can be generated with the appropriate stimulation both in vitro and in vivo, which reinforces the notion that factors present in the microenvironment may play a crucial role in the induction of Breg cells. 8 Certain TLR agonists have been demonstrated to be potent inducers of B cells with suppressive functions. LPS from Gram-negative bacteria and CpG-containing oligonucleotides that mimic bacterial DNA have been shown to induce IL-10-producing B cells and inhibit disease progression in a mouse model of EAE. 90 Mice containing B-cell deletions of Tlr2, Tlr4 or the TLR adaptor myeloid differentiation primary-response gene 88 (MyD88) could not recover from EAE, suggesting that TLRs are directly involved in modulating the regulatory function of B cells. 90 TLR-signaling has been shown to initiate IL-10 production in naive B cells. However, B cells also require CD40 and BCR ligation to enable further IL-10-production. 60 Accumulating data support a two-step model for the establishment of B-cellmediated suppression. During the initial stage, TLR stimulation induces only a few IL-10-producing B cells. During the second phase, BCR and CD40 ligation, which are classically involved in B-cell survival and expansion, further amplifies the population of IL-10-producing B cells, which results in sufficient IL-10 production for effective suppression. 90 Yanaba et al. have demonstrated that splenic B cells treated with LPS, PMA and ionomycin in vitro for 5 h results in optimal IL-10 production. 91 Moreover, LPS or LPS plus CD40 stimulation for 48 h induces additional splenic CD1d hi CD5
1 B10 cells to express IL-10 following PMA plus ionomycin stimulation. Human B cells express TLR9, which is a receptor for CpG, but not TLR4. Bouaziz et al. have shown that TLR9 is a potent inducer of IL-10 production. Moreover, the optimal stimulus for human B cells found in the blood is the combination of CpG and anti-Ig, which can act synergistically to induce human B cells to produce IL-10. 82 Interestingly, CpG and anti-Ig stimuli can effectively induce memory B cells (CD27 43 In contrast, mice with chimeric bone marrow that contained B cells lacking CD40 expression failed to recover from EAE. However, the transfer of B cells from mice that had recovered from EAE into these chimeric mice compensated for their inability to recover from EAE. 60 In humans, B cells from the blood that were treated with CD40L effectively induced CD4 hi B cells from the peripheral blood of SLE patients were insensitive to stimulation by CD40L and produced a reduced amount of IL-10. Consequently, these B cells were unable to suppress CD4
1

CD25
2 T cells from healthy donors. 10 These results suggest that anti-CD40 ligation is critically involved in Breg cell activation.
B-cell activating factor (BAFF), which is a member of the TNF family, acts as a key regulator of B-cell maturation and survival. Analyses of BAFF-deficient mice reveal a fundamental role of BAFF in promoting the maturation of T1 B cells to T2 B cells. 94 In addition to the crucial role BAFF plays in the maintenance of the peripheral B cell pool, BAFF has been found to be essential for MZ B-cell development. 95 Moreover, new evidence from BAFF-transgenic mice indicates that BAFF induces CD4 1 Foxp3 1 T cells to suppress T-cell responses in an indirect, B cell-dependent manner, which suggests a regulatory role of BAFF in vivo. 96 Recently, we have shown that low dosages of BAFF can induce B cells of the phenotype CD1d hi CD5 1 to induce IL-10, which is similar to B10 cells. BAFF stimulation can selectively induce the expansion of IL-10-producing B cells after 3-days in culture. Moreover, BAFF treatment in vivo increased the number of IL-10-producing B cells in the marginal zone regions. 46 These findings reveal a previously unappreciated function of BAFF, which is to induce B cells with regulatory function.
In addition, other signals have been reported to be important in the generation of Breg cells. For example, apoptotic cells (ACs) have been shown to act as endogenous signals that trigger IL-10 production, leading to the amelioration of CIA. 97 ACs are able to induce splenic B cells to secrete IL-10, which further enhances antigen-specific T cells to secrete IL-10 and exert immunosuppressive functions. Moreover, ACs can preferentially induce MZ B cells, rather than FO B cells, to secrete IL-10, which is most likely related to the fact that MZ B cells reside on the border between the red and white pulp in the spleen. 98 23 These results suggest that Breg cells can be generated in the appropriate temporal and spatial microenvironment. Future studies identifying more signals involved in the differentiation of B cells into Breg cells are anticipated.
MECHANISMS UNDERLYING BREG CELL FUNCTION
There are several direct and indirect mechanisms by which Breg cells exert their regulatory functions during the immune response (Figure 1 ). In mice, there are currently two well-characterized subsets of IL-10-producing B cells. The first is a B10 cell subset with the phenotype CD19 hi CD1d hi CD5 1 , and the second is a T2-MZP cell subset with the phenotype CD19
Although the frequency of naturally existing IL-10-producing regulatory B cells is extremely low, Breg cells can be expanded in vitro. This expansion allows for the enrichment of Breg cells and permits a more comprehensive study of the mechanisms by which Breg cells mediate immune suppression. These two Breg subsets produce IL-10 and suppress both the proliferation of T cells and cytokine production (IFN-c 101 B cells can also promote DCs to not only secrete IL-4 but also downregulate IL-12, which affects the Th1/Th2 balance. 102 In addition to IL-10-producing Breg cells, TGF-b1-producing Breg cells have been identified in response to LPS stimulation in vitro. 103, 104 These B cells can trigger pathogenic Th1 cells to undergo apoptosis through Fas-FasL interactions and/or the inhibition of antigen-presenting cell activity via the secretion of TGF-b1. 103 In addition to regulating the Th1/Th2 balance, Breg cells have been shown to affect the balance between Foxp3 1 and IL-17-producing T cells. 101, 105 Worm-induced Breg cells have been shown to suppress allergic airway inflammation by 
Foxp3
1 Treg cells, which is a IL-10-dependent but TGF-b-independent mechanism. 105, 106 Carter et al. have elegantly demonstrated that endogenous IL-10-producing B cell-deficient mice develop an exacerbated case of arthritis and exhibit an increased frequency of Th1/Th17 pro-inflammatory cells, but a decreased frequency of Treg cells. 101, 107 Consistent with these findings, we have also demonstrated that B10 cells induced in vitro can suppress Th17 cell differentiation by decreasing the phosphorylation levels of Stat3, which subsequently reduces the levels of RORct, and partially inhibits the Th17 cell population in an IL-10-dependent manner. 45 Based on these current findings, it is likely that Breg cells play an important role in T-cell plasticity.
Apart from cytokine-mediated suppression, B cells can also exert their regulatory effects by cellular interactions. Both B10 and T2-MZP Breg cells share the phenotype CD1d hi , which is a MZ B cell marker. CD1d-expressing MZ B cells have been shown to activate invariant natural killer T (iNKT) cells in the presence of DCs and aid in the establishment of peripheral tolerance by the induction of Tr1 cells, which is a process that is dependent on the activation of iNKT cells via CD1d. 108, 109 Moreover, CD1d
hi MZ B cells are capable of presenting glycolipids through CD1d. These glycolipids are recognized by NKT cells, which are cells that have been shown to play important roles in autoimmune development. Interestingly, EAE is exacerbated in CD1d 2/2 mice, which lack NKT cells. 110 Recently, human transitional B cells (CD19 1 CD24 hi CD38 hi ) have been shown to play an essential role in iNKT cell expansion and activation in healthy individuals, but not in SLE patients because transitional B cells from SLE patients have defects in CD1d recycling. 111 Thus, CD1d-expressing Breg cells can exert their regulatory functions by activating NKT cells.
The mechanisms for regulating the immune response are mediated by either the release of suppressive soluble cytokines, including IL-10 and TGF-b, by regulatory cells or promotion of activation-induced cell death (or apoptosis), which is mediated by death-inducing ligands, including FasL, TNF-related apoptosis-inducing ligand, and programmed death ligands 1 and 2 (PD-L1 and PD-L2), etc.
112-114 B cells can express FasL and other death-inducing ligands under many circumstances. Both FasL and IL-10 are highly expressed in the CD5 1 B-cell population, which indicates that CD5 1 B cells may exert regulatory effects by their killing ability. 7 Interestingly, a recent study by Ray et al. has suggested that B cells can induce the proliferation of Treg cells in the CNS during the development of EAE via the expression of glucocorticoid-induced TNF receptor ligand rather than IL-10. 115 In addition, costimulatory molecules are also involved in Breg-mediated suppression. The synergistic effects of IL-10, CD80 and CD86 interactions have been demonstrated in both mouse and humans. 10, 116 Thus, signaling through CD80 and CD86 is an additional effector mechanism for immune suppression.
In summary, Breg cells can exert their suppressive effects by secreting anti-inflammatory cytokines, such as IL-10 and TGFb, and engaging in cell-to-cell contact via activating cell death markers or costimulatory molecules. Moreover, Breg cells can not only regulate the balance of T helper cells, but also induce tolerogenic DC or invariant NKT cells to further influence T helper cell plasticity.
CONCLUDING REMARKS: BREG CELLS FROM BENCH TO BEDSIDE
The pathogenic roles of B cells in autoimmune diseases have been extensively characterized. These roles have been further confirmed by the efficacy of B-cell depletion in treating autoimmune diseases in both humans and mice. Although B celltargeted therapies are very promising, long-term B-cell depletion may lead to the development of immunopathology. CD20 is expressed on B cells ranging from the pre-B to mature stages, but not on plasma cells, which suggests that long-lived plasma cells that produce autoantibodies may not be affected by anti-CD20 mAb treatment. Moreover, current approaches to target B cells cannot distinguish between pathogenic B and Breg cells. Recently, the anti-BAFF mAb has been shown to be effective in treating autoimmune diseases such as SLE. Although blocking BAFF can inhibit the survival and maturation of B cells that contribute to autoimmune pathogenesis, this approach may also reduce the number of IL-10-producing Breg cells. Because low dosages of BAFF induce the generation of Breg cells, the timing and choice of suitable antibodies for B cell depletion is critical depending on the pathogenic features of each autoimmune disease. Increasing evidence indicates that B-cell depletion results in long-term remission, which is most likely due to the expansion of Treg and Breg cells. In particular, recent studies from various mouse models have suggested that B-cell depletion leads to an increased Breg cell subset in the reconstituted B-cell population. Thus, it would be of interest to determine the effects of the adoptive transfer of Breg cells either alone or in combination with B-cell depletion for the treatment of autoimmune diseases.
The adoptive transfer of Breg cells is a potential therapeutic strategy. IL-10-producing Breg cells can continually secrete IL-10, whereas the direct administration of IL-10 has a restricted therapeutic effect due to its short half-life. There is also compelling evidence that transferred Breg cells can migrate to local inflammatory sites and reside in joint tissue for more than 3 weeks in CIA mice. Hence, Breg cells may exert regulatory functions in local sites depending on their homing capacity and the survival signals present in the local environment. However, there are also some critical questions that need to be addressed before the clinical application of Breg cells can be considered. Similar to the therapeutic application of Treg cells, one of the major challenges is the functional stability of transferred Breg cells in vivo. Thus, further characterization of the functional features of Breg cells in vivo will provide a more complete understanding of the roles Breg cells play in autoimmune pathogenesis. The knowledge gained is essential to facilitate the development of Breg cells as a potential cellular therapy for human autoimmune diseases. 
